ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
Operating Expenses
ABL Bio Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Operating Expenses
-â‚©92.8B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
![]() |
Celltrion Inc
KRX:068270
|
Operating Expenses
-â‚©1.2T
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-23%
|
|
![]() |
SK Bioscience Co Ltd
KRX:302440
|
Operating Expenses
-â‚©169.4B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Operating Expenses
-â‚©120.9B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Operating Expenses
-â‚©125.2B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-34%
|
|
![]() |
Alteogen Inc
KOSDAQ:196170
|
Operating Expenses
-â‚©38.7B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-28%
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Operating Expenses?
Operating Expenses
-92.8B
KRW
Based on the financial report for Dec 31, 2024, ABL Bio Inc's Operating Expenses amounts to -92.8B KRW.
What is ABL Bio Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-16%
Over the last year, the Operating Expenses growth was -36%. The average annual Operating Expenses growth rates for ABL Bio Inc have been -17% over the past three years , -16% over the past five years .